Pharmacology
Enzyme Kinetics (Michaelis-Menten)
v = Vmax·[S] / (Km + [S]) — the equation behind every enzyme drug
Michaelis-Menten kinetics models enzyme velocity as v = Vmax·[S]/(Km+[S]). Km is the substrate concentration at half-maximal rate — the foundation of every drug-enzyme interaction.
- Equationv = Vmax·[S] / (Km + [S])
- Km meaning[S] at v = Vmax/2 (affinity proxy)
- Hexokinase Km~0.04 mM glucose (high affinity)
- Glucokinase Km~10 mM glucose (post-prandial sensor)
- Competitive inhibitorKm rises, Vmax unchanged
- Non-competitive inhibitorVmax falls, Km unchanged
Interactive visualization
Press play, or step through manually. The visualization is yours to drive — try it before reading on.
Watch the 60-second explainer
A condensed visual walkthrough — narrated, captioned, under a minute.
How Michaelis-Menten kinetics works
Imagine an enzyme E and substrate S. They bind reversibly to form the enzyme-substrate complex ES, which then breaks down — usually irreversibly on the time scale of catalysis — into enzyme plus product. Leonor Michaelis and Maud Menten derived in 1913 the equation that bears their names by assuming that the ES complex reaches a steady-state concentration almost immediately after mixing: the rate of formation equals the rate of breakdown. With that single assumption the algebra collapses to v = Vmax·[S]/(Km+[S]). The curve of v versus [S] is a rectangular hyperbola — linear at low [S], saturating at high [S], passing through exactly half of Vmax when [S] equals Km.
Vmax = kcat·[E]total, the ceiling rate when every active site is occupied. Km ≈ (k-1+kcat)/k1, a composite of binding and turnover rate constants. Low Km implies the enzyme grips substrate well even at trace concentrations; high Km implies the enzyme needs abundant substrate to be efficient.
Worked example — hexokinase versus glucokinase
Both enzymes phosphorylate glucose to glucose-6-phosphate, the entry step of glycolysis. Hexokinase (in muscle, brain, most tissues) has Km ≈ 0.04 mM. Blood glucose at fasting sits around 5 mM — about 100× above hexokinase Km. Plug into Michaelis-Menten: v ≈ Vmax·5/(0.04+5) ≈ 0.99 Vmax. Hexokinase runs essentially at its ceiling all the time. That is why brain cells can always phosphorylate any glucose they pick up.
Glucokinase (in liver and pancreatic β-cells) has Km ≈ 10 mM. At a fasting 5 mM, v ≈ Vmax·5/(10+5) ≈ 0.33 Vmax. Glucokinase is only one-third engaged when blood sugar is normal. After a carbohydrate meal, glucose can climb to 10 mM — now v ≈ 0.50 Vmax. Glucokinase doubles its rate exactly when extra glucose disposal is needed. The high-Km design makes liver and β-cell glucose sensors switch on only post-prandially. MODY-2 diabetes is caused by glucokinase mutations that nudge Km upward — the β-cell does not "see" hyperglycemia until later, and insulin secretion is delayed.
Famous application — Lineweaver-Burk linearization
Before non-linear regression was easy, biochemists inverted Michaelis-Menten to a straight line: 1/v = (Km/Vmax)·(1/[S]) + 1/Vmax. The y-intercept is 1/Vmax, the x-intercept is −1/Km, and the slope is Km/Vmax. The double-reciprocal plot makes inhibitor type immediately visible: competitive inhibitors fan out from the same y-intercept (Vmax unchanged) but shifted x-intercept (Km changed); non-competitive inhibitors share the x-intercept but have raised y-intercept (Vmax changed); uncompetitive inhibitors give parallel lines (both Km and Vmax fall in the same ratio).
Why enzyme kinetics matters in medicine
- Drug design. Statins compete with HMG-CoA at HMG-CoA reductase; their Ki values (nanomolar) explain why low doses block cholesterol synthesis effectively.
- Toxicology. Methanol poisoning is treated with fomepizole — a competitive inhibitor of alcohol dehydrogenase — that buys time to clear methanol before it metabolizes to toxic formate.
- Saturable clearance. Phenytoin has Michaelis-Menten elimination; small dose increases above the saturation point produce dangerous level jumps, so dosing must be titrated by trough levels.
- Pharmacogenomics. CYP2D6 poor metabolizers have effectively no enzyme; codeine cannot be converted to morphine, while ultrarapid metabolizers reach toxic morphine levels.
- Diagnosis. Glucokinase Km mutations cause MODY-2 with mild fasting hyperglycemia and minimal long-term complications — distinct from type 2 diabetes.
- Cancer therapy. Methotrexate inhibits dihydrofolate reductase competitively; high-dose methotrexate plus folinic acid rescue exploits the rapid recovery of normal cells once drug is washed out.
- Enzyme replacement. Knowing Vmax and Km of replacement enzymes (alglucosidase alfa in Pompe disease) sets correct dosing intervals to maintain substrate clearance.
Common misconceptions
- "Km equals binding affinity." Only when kcat is much smaller than k-1. Otherwise Km is a composite of binding and catalytic steps.
- "Higher Vmax means a better enzyme." Better depends on context — for low-substrate tissues, kcat/Km matters more than raw Vmax.
- "Competitive inhibitors lower Vmax." They do not. Enough substrate always overcomes a pure competitive inhibitor.
- "All enzymes follow Michaelis-Menten." Allosteric enzymes (PFK, hemoglobin) give sigmoidal curves and need the Hill equation.
- "Linear v versus [S] plots prove Michaelis-Menten." Only at [S] much less than Km. You must sample [S] above and below Km to fit it.
- "Irreversible inhibitors have a Ki." They are described by kinact and KI (potency of the covalent reaction), not the equilibrium Ki of reversible binding.
| Inhibitor | Binds where | Km change | Vmax change | Example | Lineweaver-Burk |
|---|---|---|---|---|---|
| None | — | baseline | baseline | — | reference line |
| Competitive | active site | ↑ (apparent) | unchanged | methotrexate at DHFR | same y-intercept |
| Non-competitive | allosteric | unchanged | ↓ | doxycycline at MMPs | same x-intercept |
| Uncompetitive | ES complex only | ↓ (apparent) | ↓ | lithium at IMPase | parallel lines |
| Mixed | both E and ES | ↑ or ↓ | ↓ | many natural products | intersect off-axis |
| Irreversible | covalent active site | n/a | ↓ progressively | aspirin at COX | shifts over time |
Frequently asked questions
What is the Michaelis-Menten equation?
v = Vmax·[S]/(Km + [S]). Reaction velocity v depends on substrate concentration [S], the enzyme's maximum rate Vmax, and Km — the substrate concentration at which v equals Vmax/2. At low [S] the rate climbs almost linearly with substrate; at saturating [S] it plateaus at Vmax because every active site is occupied. The hyperbolic curve is the visual fingerprint of single-site, single-substrate enzyme kinetics.
What does Km tell you?
Km is the substrate concentration at half-maximal velocity, in molar units (mM, μM, nM). Low Km = high apparent affinity — hexokinase binds glucose with Km around 0.04 mM, so it phosphorylates glucose efficiently even at low blood sugar. High Km = lower affinity but a regulatory threshold — glucokinase Km is around 10 mM, near post-prandial blood glucose, so it only engages after meals. Km is independent of enzyme concentration; Vmax scales linearly with enzyme.
How do competitive inhibitors change kinetics?
A competitive inhibitor binds the same active site as the substrate. It raises apparent Km — more substrate is needed to reach half-maximal velocity — but Vmax is unchanged because at high enough [S] the substrate outcompetes the inhibitor. Methotrexate competes with dihydrofolate at DHFR; statins compete with HMG-CoA at HMG-CoA reductase; allopurinol competes with hypoxanthine at xanthine oxidase. On a Lineweaver-Burk plot, lines intersect on the y-axis.
Non-competitive and irreversible inhibitors?
Non-competitive inhibitors bind a separate allosteric site and reduce functional enzyme: Vmax falls, Km stays the same. No amount of substrate restores activity. Irreversible inhibitors covalently modify the enzyme — aspirin acetylates COX, omeprazole disulfide-binds H+/K+-ATPase, organophosphates phosphorylate acetylcholinesterase. Duration of effect then depends on enzyme resynthesis (days for COX, hours for AChE if not bridged with pralidoxime).
Why does this matter for drug dosing?
Many drugs are themselves enzyme substrates cleared by CYP450. At plasma concentrations far below the metabolizing enzyme's Km, elimination is first-order — half-life is constant. Near or above Km, the enzyme saturates and clearance becomes zero-order — small dose changes cause large concentration jumps. Phenytoin, alcohol, salicylates, and theophylline all show this Michaelis-Menten clearance behavior, which is why their levels are monitored clinically.
What is kcat and catalytic efficiency?
kcat (the turnover number) is Vmax divided by enzyme concentration — substrates converted per active site per second. Carbonic anhydrase has kcat near 10⁶/s, one of the fastest known. The ratio kcat/Km measures catalytic efficiency in the low-substrate regime and approaches the diffusion limit (~10⁸–10⁹ M⁻¹s⁻¹) for the most evolved enzymes. Comparing kcat/Km between substrates tells you which one the enzyme prefers when both are present at trace concentrations.
When does Michaelis-Menten break down?
It assumes a single active site, no cooperativity, and substrate concentration much greater than enzyme concentration. Allosteric enzymes like hemoglobin or phosphofructokinase give sigmoidal curves and need Hill coefficients instead. Multi-substrate reactions need bi-substrate variants (random vs ordered). When substrate is comparable to enzyme (tight-binding inhibitors at low enzyme levels), the simple equation overestimates activity and the Morrison equation applies. Always check that the curve is hyperbolic before fitting Km.